This article was originally published in The Gray Sheet
Executive SummarySigmoidoscope EndoSheath recalled as a result of "recent testing" indicating that a "small quantity of the product might result in a leak during use," the firm says. Risk associated with the condition is "remote," while no customer complaints have been received suggesting the occurrence of a leak, Vision Sciences notes
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.